Agilent Technologies (A): Junto Capital Management LP exited its position 185K shares
Junto Capital Management LP exited its position in Agilent Technologies, per its Q1 2025 13F.
- 185K
- Prior-quarter shares · no longer reported
- Holdings as of
- Mar 31, 2025
- Filed
- May 15, 2025
What stands out in this filing
- The manager reported no shares in Q1 2025, after 184,780 in its Q4 2024 filing.
- 15 other tracked managers reported the same kind of change for Q1 2025.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Mar 3, 2025CongressDisclosed sale of A — reported range $1,001 - $15,000
- Mar 13, 2025CongressDisclosed sale of A — reported range $15,001 - $50,000
- Mar 17, 2025InsiderOfficer sold ~$233K of A shares in the open market
- Mar 20, 2025FDARecall: GenetiSure Dx Labeling Kit, REF: K1201-64105, contains human reference DNA female aliquot, REF5190-7317. A required kit for the GenetiSure Dx Postnatal assay (…
- Mar 31, 2025InsiderDirector sold ~$212K of A shares in the open market
- Apr 1, 2025CongressDisclosed partial sale of A — reported range $1,001 - $15,000
- Apr 8, 2025CongressDisclosed sale of A — reported range $1,001 - $15,000
- Apr 17, 2025CongressDisclosed purchase of A — reported range $15,001 - $50,000
- May 12, 2025CongressDisclosed sale of A — reported range $15,001 - $50,000
- May 15, 2025CongressDisclosed purchase of A — reported range $1,001 - $15,000
What came next
- Jun 17, 2025CongressDisclosed purchase of A — reported range $1,001 - $15,000
- Jun 18, 2025InsiderDirector sold ~$904 of A shares in the open market
- Jul 1, 2025InsiderCEO sold ~$177K of A shares in the open market
- Jul 16, 2025CongressDisclosed sale of A — reported range $1,001 - $15,000
- Aug 1, 2025InsiderCEO sold ~$227K of A shares in the open market
- Aug 11, 2025FDARecall: Brand Name: FLEX Monoclonal Mouse Anti-Human CD20cy, Clone L26, Ready-to-Use (Dako Omnis) Model/Catalog Number: GA60461-2 Software Version: Not applicable Prod…
- Aug 11, 2025FDARecall: Brand Name: FLEX Monoclonal Mouse Anti-Human CD20cy, Clone L26, Ready-to-Use (Dako Omnis) Model/Catalog Number: GA60461-2J Software Version: Not applicable Pro…
- Aug 11, 2025FDARecall: Brand Name: FLEX Monoclonal Mouse Anti-Human CD20cy, Clone L26, Ready-to-Use (Dako Omnis) Model/Catalog Number: GA60461-2CN Software Version: Not applicable Pr…
- Aug 15, 2025FDAFDA device approval: MMR IHC Panel pharmDx (Dako Omnis)
- Sep 2, 2025InsiderCEO sold ~$250K of A shares in the open market
How to read SEC Form 13F-HR
Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.
Full guide: What is an SEC Form 13F?
What else is on file for Agilent Technologies
For Agilent Technologies, OQRO holds 2 insider filings (SEC Form 4 or Form 144), 2 fund holdings reports (13F) and 2 federal contract awards dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its A page.
How this filing works
Explore the data
Common questions
What does this filing report about Agilent Technologies (A) stock?
Junto Capital Management LP exited its position in Agilent Technologies, per its Q1 2025 13F. Held the prior quarter, no longer listed per its Q1 2025 13F.
When did it happen, and when was it made public?
Holdings as of: Mar 31, 2025. Filed: May 15, 2025.
What stands out in this filing?
The manager reported no shares in Q1 2025, after 184,780 in its Q4 2024 filing. 15 other tracked managers reported the same kind of change for Q1 2025.
Is this a trade made on a known date?
No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.
Where does this information come from?
From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Agilent Technologies recently?
For Agilent Technologies, OQRO holds 2 insider filings (SEC Form 4 or Form 144), 2 fund holdings reports (13F) and 2 federal contract awards dated in the last 90 days. They are listed on the A page.
Does this mean A stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Agilent Technologies
- SEC Form 13F-HRNov 16, 2026
- SEC Form 13F-HRNov 16, 2026
- USAspending.gov award recordSep 29, 2026
- USAspending.gov award recordSep 28, 2026
- SEC Form 4Sep 9, 2026
- SEC Form 144Sep 4, 2026
Everything OQRO holds on this company is on its A page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
